Why EdgeCase Capital Partners: Interviews, Careers, & Portfolio

EdgeCase Capital Partners Overview

EdgeCase Capital Partners is a venture capital group dedicated to supporting innovation and creating impact in early-stage software startups.

As a generalist firm, EdgeCase Capital Partners has a keen interest in AI technology and FinTech, offering angel and early-stage investments ranging from $25,000 to $100,000.

The firm targets a diverse range of startups, including those founded and managed by college students. The firm seeks disruptive early-stage technology startups led by passionate, talented, and deeply engaged management teams.

What EdgeCase Capital Partners offers:

• Lead Investor: Taking the lead in investment rounds.
• Capital: Providing funds to fuel growth.
• Expertise: Offering talent and seasoned guidance.
• Connections: Access to a vast network of additional capital and investors.
• Consulting Services: SpeedRun Consulting identifies and addresses gaps in accounting, finance, software, and more, providing needed resources.
• Experienced Team: A proven track record in researching and identifying promising startups.

Based in San Francisco, CA, and founded in 2021 by Caden Moskowitz, EdgeCase Capital Partners is committed to driving the success of early-stage software startups through strategic investments and comprehensive support.

EdgeCase Capital Partners AUM

As of writing, there is no publicly available information regarding the assets under management of EdgeCase Capital Partners.

EdgeCase Capital Partners Interview Process & Questions

Firms often adjust their interview process for each candidate, but if you interview at EdgeCase Capital Partners (or similar firms), you can generally expect the following:

• Around 4-6 interview rounds.
• Initial interviews typically led by junior investment professionals or the HR team, with senior staff conducting later rounds.
• The entire process usually spans several weeks unless it’s during “on-cycle” or “on-campus” recruiting.

Interviews at EdgeCase Capital Partners typically include a mix of fit, behavioral, and technical/investing questions.

If you need assistance with interview preparation, consider my Growth Equity Interview Guide.

Why EdgeCase Capital Partners

“Why this firm?” is one of the most common and crucial interview questions.

If you’ve networked with people from the firm, mention them and how their positive impression influenced your interest.

It’s also wise to research the firm before your interview. A great way to do this is by listening to interviews with its founders or investors.

For example, here’s a discussion with Caden Moskowitz, Founding Partner at EdgeCase Capital Partners:

EdgeCase Capital Partners Case Study

Interviewees are almost always presented with a case study during interviews. These case studies allow firms to evaluate your technical skills and communication abilities.

At firms like EdgeCase Capital Partners, case studies typically focus on financial modeling and investment recommendations. For junior roles, a cold calling case study is often included as well.

If you need help getting ready for case studies, check out my Growth Equity Interview Guide course.

EdgeCase Capital Partners Salary & Compensation

According to Glassdoor, EdgeCase Capital Partners offers median total pay of $126K and $242K per year to their investment analysts and associates, respectively. Figures will vary depending on several factors such as experience, skills, and education.

Analyst

Associate

EdgeCase Capital Partners Careers, Jobs, & Internships

To see open roles at EdgeCase Capital Partners, check out our job board which features all open roles for them and other similar firms.

EdgeCase Capital Partners Portfolio & Investments

According to the firm’s list of portfolio companies, EdgeCase Capital Partners has made 17 investments. Some of their notable deals include Gatchi, Slushy, and Rivia Health.

Notable Transaction: PhorMed

EdgeCase Capital Partners made a significant investment with PhorMed, a developer of a clinical-phase compound designed for gene repair therapy.

PhorMed’s innovative RP-323 compound targets damaged or mutated cells caused by cancer and viruses. This compound has the unique ability to pass through the blood-brain barrier and neurological cells, enabling medical research companies to address the root causes of diseases rather than just the symptoms. This approach facilitates the body’s natural repair processes, aiming to restore health.

PhorMed is focused on leveraging gene therapy to treat diseases, offering new hope to patients suffering from conditions such as AML, Hodgkin’s Lymphoma, ARDS, Parkinson’s disease, and various viruses.

In addition to EdgeCase Capital Partners, PhorMed has attracted investment from Dark Knight Capital Ventures, showing the confidence in PhorMed’s potential to revolutionize treatment for numerous diseases through cutting-edge gene therapy.

Next Steps

If you’re aiming to become a part of the professional investment team at EdgeCase Capital Partners, I highly recommend my Growth Equity Interview Guide.

This self-paced online course is designed for professionals aspiring to break into growth equity, improving their chances of landing their desired investing role. The course covers essential concepts commonly encountered in interviews, including case studies, financial modeling, and more.

Start your interview preparation today!